Outpatient administration of CAR T-cell therapies can reduce costs and improve patient satisfaction, with evolving ...

Dr. Debu Tripathy explains how ctDNA is used to in breast cancer detection and how it can also indicate the presence of MRD. Circulating tumor DNA (ctDNA) is described by The University of Texas MD ...

Foresight Diagnostics and the University of Washington School of Medicine and Fred Hutch Cancer Center have announced the launch of the PRECISE-HL trial, which will use the Foresight Clarity ...

CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed. Circulating tumor DNA (ctDNA) negativity has been ...

Approximately 25% of patients had ctDNA- or imaging-confirmed recurrence. More than 30% had evidence of recurrence by imaging that ctDNA did not identify. The addition of serial circulating tumor ...

End of therapy ctDNA-MRD analysis will also be an exploratory endpoint for the trial. For more information about the PRECISE-HL study, including eligibility and detailed protocol, please visit ...

The New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) recently approved the enhanced version of the clonoSEQ ctDNA assay for the detection and monitoring of MRD in ...

Employing PhasED-Seq technology, the test is a circulating tumour DNA (ctDNA)-based minimal residual disease (MRD) LDT. The trial aims to evaluate the possibility of decreasing chemotherapy ...

Currently, the standard treatment for newly diagnosed advanced cHL patients involves several cycles of chemotherapy. Recent studies have explored combining new therapies, such as PD-1 inhibitors ...